Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Next shoe drops

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on Dec 11, 2024 11:38am

86 Views

Post# 36356744

RE:Next shoe drops

My take is that the IR hiring is timed due to Thera finally turning a corner and in dire need of filling the IR vacuum…I think they have not yet updated the corporate presentation because there is a size 13 shoe dropping soon related to some form of a Sort1+ platform deal.

Scarlet, my wife & I felt we needed to one up your single Shih tzu avatar with our festive holiday DOUBLE Shih tzu avatar, full disclosure that the boys are not spoiled, they are simply well cared for

Mannequin wrote:
Announcement of paying off Marathon

FDA approval for EGRIFTA by end of month.

Annoucing adding new patients to higher dose by end of month

F8 approval

Partner for Phase 2 in advance of results for Phase 1c? Not sure what it is.